Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ: RVNC )

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average... 
Via Benzinga
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over... 
Via Benzinga
With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor
Via Benzinga
Analyst Ratings for Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know
Needham has decided to maintain its Buy rating of Revance Therapeutics (NASDAQ:RVNC) and raise its price target from $25.00 to $35.00. Shares of Revance Therapeutics are trading up 9.72% over the last... 
Via Benzinga
What 5 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
5 Analysts Have This to Say About Revance Therapeutics
Within the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings: 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst
Via Benzinga
Revance Therapeutics: Q2 Earnings Insights
  Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022
Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details! 
Via InvestorPlace
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. 
Via Benzinga
Why Is Revance Therapeutics (RVNC) Stock Soaring Today?
RVNC stock is jumping 12% after the FDA approved its alternative to AbbVie's Botox. Revance's injection is supposed to last longer than Botox. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of... 
Via Benzinga
Why Asana Is Trading Higher By 24%; Here Are 24 Stocks Moving Premarket
Gainers Asana, Inc. (NYSE: ASAN) rose 24.1% to $23.62 in pre-market trading after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. 
Via Benzinga
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
From Revance Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Revance Therapeutics: Earnings Outlook
  Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter. 
Via Benzinga
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.